UY35013A - Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos - Google Patents

Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos

Info

Publication number
UY35013A
UY35013A UY0001035013A UY35013A UY35013A UY 35013 A UY35013 A UY 35013A UY 0001035013 A UY0001035013 A UY 0001035013A UY 35013 A UY35013 A UY 35013A UY 35013 A UY35013 A UY 35013A
Authority
UY
Uruguay
Prior art keywords
methods
antagonist
pharmaceutical compositions
compositions containing
subject
Prior art date
Application number
UY0001035013A
Other languages
English (en)
Inventor
Ardeleanu Marius
Stephane C Kirkesseli
Kundu Sudeep
Graham Neil
Jennifer Davidson Hamilton
Ming Jeffrey
Radin Allen
Ross E Rocklin
Steven P Weinstein
Original Assignee
Sanofi Sa
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, Regeneron Pharma filed Critical Sanofi Sa
Publication of UY35013A publication Critical patent/UY35013A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención proporciona métodos para tratar la dermatitis atópica (DA). También se proporcionan métodos para mejorar uno o más parámetros asociados con la DA, y métodos para reducir el nive l de al menos un biomarcador asociado con la DA en un sujeto que lo necesita. Los métodos de la presente invención comprenden administrar a un sujeto que lo necesita una composición farmacéutica que comprende un antagonista del receptor de interleucina-4 (IL-4R) tal como un anticuerpo anti-IL-4R.
UY0001035013A 2012-09-07 2013-09-06 Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos UY35013A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261697972P 2012-09-07 2012-09-07
US201261738715P 2012-12-18 2012-12-18
US201361748588P 2013-01-03 2013-01-03
US201361764624P 2013-02-14 2013-02-14
US201361768229P 2013-02-22 2013-02-22
US201361770091P 2013-02-27 2013-02-27
US201361782420P 2013-03-14 2013-03-14
US201361816191P 2013-04-26 2013-04-26
FR1356759 2013-07-10

Publications (1)

Publication Number Publication Date
UY35013A true UY35013A (es) 2014-03-31

Family

ID=50233497

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035013A UY35013A (es) 2012-09-07 2013-09-06 Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos

Country Status (29)

Country Link
US (3) US20140072583A1 (es)
EP (4) EP3889181B1 (es)
JP (3) JP6353838B2 (es)
KR (3) KR102576903B1 (es)
CN (3) CN104995212A (es)
AR (1) AR092475A1 (es)
AU (4) AU2013312868B2 (es)
BR (1) BR112015005048A8 (es)
CA (1) CA2883936C (es)
CY (1) CY1121906T1 (es)
DK (1) DK2892927T3 (es)
ES (1) ES2675779T3 (es)
HK (1) HK1209132A1 (es)
HR (1) HRP20181227T1 (es)
HU (1) HUE039387T2 (es)
IL (1) IL237328B (es)
LT (1) LT2892927T (es)
MX (1) MX363193B (es)
NZ (3) NZ731864A (es)
PL (1) PL2892927T3 (es)
PT (1) PT3889181T (es)
RS (1) RS57520B1 (es)
RU (2) RU2666630C2 (es)
SG (2) SG10201701798TA (es)
SI (1) SI2892927T1 (es)
TR (1) TR201808181T4 (es)
TW (4) TWI699212B (es)
UY (1) UY35013A (es)
WO (1) WO2014039461A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733711A1 (en) 2010-10-06 2020-11-04 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
PL3470432T3 (pl) 2012-08-21 2022-02-07 Sanofi Biotechnology Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
AU2013312868B2 (en) * 2012-09-07 2018-03-22 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
SI3010539T1 (sl) 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CN106232140A (zh) 2014-02-21 2016-12-14 赛诺菲生物技术公司 通过施用il‑4r拮抗剂治疗或预防哮喘的方法
US10370449B2 (en) * 2014-02-28 2019-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
BR112017020915A2 (pt) 2015-04-02 2018-07-10 Intervet Int Bv ?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
CN107614016B (zh) 2015-04-14 2022-06-17 中外制药株式会社 包含il-31拮抗剂作为活性成分的用于预防和/或治疗特应性皮炎的药物组合物
KR20180110089A (ko) 2016-02-19 2018-10-08 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함으로써 백신의 효능을 향상시키는 방법
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CA3035202A1 (en) * 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
AU2017332732B2 (en) 2016-09-22 2024-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR102557643B1 (ko) 2016-09-23 2023-07-20 제넨테크, 인크. 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
HUE064655T2 (hu) 2017-10-30 2024-04-28 Sanofi Biotechnology IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
KR20200110302A (ko) * 2017-10-31 2020-09-23 원니스 바이오테크 컴퍼니 리미티드 IgE-매개 알레르기성 질환들의 치료
AU2018360059B2 (en) 2017-11-03 2023-07-13 Aclaris Therapeutics, Inc. Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same
US20210065248A1 (en) * 2018-01-31 2021-03-04 Medidoc Search Inc. Advertisement presentation method and advertisement presentation system
CA3099066A1 (en) * 2018-05-13 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
CA3109192A1 (en) 2018-08-10 2020-02-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
WO2020092015A1 (en) * 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
EP3941589A1 (en) 2019-03-21 2022-01-26 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN111592597B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11748800B1 (en) * 2019-09-11 2023-09-05 Life Spectacular, Inc. Generating skin care recommendations for a user based on skin product attributes and user location and demographic data
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
AU2020399975A1 (en) 2019-12-09 2022-07-28 Sanofi Biotechnology Methods for treating digitally-identified IL-4/IL-13 related disorders
BR112022015363A2 (pt) 2020-03-27 2022-09-20 Regeneron Pharma Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
EP4019090A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-4r
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
AU2021405060A1 (en) 2020-12-23 2023-06-22 Numab Therapeutics AG Antibody variable domains that bind il-4r
US11581084B2 (en) * 2020-12-29 2023-02-14 Kpn Innovations, Llc. Systems and methods for generating an alimentary plan for managing skin disorders
TW202302104A (zh) * 2021-02-18 2023-01-16 美商阿克拉里斯醫療股份有限公司 Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法
WO2023028468A1 (en) 2021-08-23 2023-03-02 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
WO2024076731A1 (en) * 2022-10-06 2024-04-11 Regranion, Llc Methods and compositions for treating hidradenitis suppurativa
US20240141051A1 (en) 2022-11-01 2024-05-02 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3315427B2 (ja) * 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP3190126A1 (en) 2000-05-26 2017-07-12 Immunex Corporation Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
CN100496579C (zh) * 2000-07-26 2009-06-10 株式会社凤凰堂 止痒性组合物和促进创伤治愈的组合物
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
EP1891111A1 (en) 2005-05-06 2008-02-27 ZymoGenetics, Inc. Il-31 monoclonal antibodies and methods of use
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP3733711A1 (en) 2010-10-06 2020-11-04 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (ru) * 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
AU2013312868B2 (en) * 2012-09-07 2018-03-22 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R antagonist

Also Published As

Publication number Publication date
TWI699212B (zh) 2020-07-21
BR112015005048A2 (pt) 2017-11-21
CA2883936A1 (en) 2014-03-13
AR092475A1 (es) 2015-04-22
AU2013312868A1 (en) 2015-03-12
NZ630178A (en) 2017-06-30
TWI690328B (zh) 2020-04-11
EP2892927A1 (en) 2015-07-15
EP3889181B1 (en) 2024-04-24
TWI814575B (zh) 2023-09-01
IL237328B (en) 2020-06-30
RU2698907C2 (ru) 2019-09-02
AU2018204346A1 (en) 2018-07-05
KR102385501B1 (ko) 2022-04-14
AU2013312868B2 (en) 2018-03-22
NZ748451A (en) 2023-04-28
TW201822816A (zh) 2018-07-01
BR112015005048A8 (pt) 2018-01-30
CY1121906T1 (el) 2020-07-31
NZ731864A (en) 2022-07-01
IL237328A0 (en) 2015-04-30
TR201808181T4 (tr) 2018-07-23
MX2015002873A (es) 2015-11-13
WO2014039461A1 (en) 2014-03-13
KR20150048887A (ko) 2015-05-07
PL2892927T3 (pl) 2018-11-30
US20170333557A1 (en) 2017-11-23
PT3889181T (pt) 2024-05-29
HRP20181227T1 (hr) 2018-10-05
ES2675779T3 (es) 2018-07-12
DK2892927T3 (en) 2018-07-16
RU2018131237A3 (es) 2019-03-14
SG10201701798TA (en) 2017-04-27
AU2018204346B2 (en) 2019-10-03
AU2021236538B2 (en) 2023-11-09
AU2019279946B2 (en) 2021-07-01
CN118286417A (zh) 2024-07-05
AU2019279946A1 (en) 2020-01-16
RU2666630C2 (ru) 2018-09-11
SI2892927T1 (sl) 2018-10-30
HUE039387T2 (hu) 2018-12-28
RS57520B1 (sr) 2018-10-31
HK1209132A1 (en) 2016-03-24
JP2023082091A (ja) 2023-06-13
EP4374919A2 (en) 2024-05-29
SG11201501011WA (en) 2015-03-30
JP2018154648A (ja) 2018-10-04
CA2883936C (en) 2022-01-11
MX363193B (es) 2019-03-14
CN118286430A (zh) 2024-07-05
KR20210095731A (ko) 2021-08-02
LT2892927T (lt) 2018-09-10
TW201414493A (zh) 2014-04-16
JP2015534548A (ja) 2015-12-03
KR20220049047A (ko) 2022-04-20
JP6637113B2 (ja) 2020-01-29
TW202325341A (zh) 2023-07-01
TW202412839A (zh) 2024-04-01
EP3354663A1 (en) 2018-08-01
EP2892927B1 (en) 2018-05-09
RU2018131237A (ru) 2018-10-04
KR102122708B1 (ko) 2020-06-17
JP6353838B2 (ja) 2018-07-04
CN104995212A (zh) 2015-10-21
US20140072583A1 (en) 2014-03-13
EP3889181A1 (en) 2021-10-06
KR102576903B1 (ko) 2023-09-13
RU2015108073A (ru) 2016-10-27
US20230058395A1 (en) 2023-02-23
AU2021236538A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
BR112015011933A8 (pt) Composições bacterianas sinérgicas e métodos de produção e uso das mesmas
GT201400164A (es) Compuestos de imidazopirrolidinona
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
CL2015002609A1 (es) 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.
IN2015DN03029A (es)
CL2015002655A1 (es) Moduladores de p2x7
PH12014502602A1 (en) Methods for improving safety of blood-brain barrier transport
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
MX2016002571A (es) Regulador de ph de transduccion.
CR20140493A (es) Compuestos novedosos
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
AR085335A1 (es) Polipeptidos interleuquina-2 mutantes
CL2015002616A1 (es) 7-azabiciclos sustituidos y su uso como modulares del receptor de orexina.
DOP2014000090A (es) Compuestos con actividad nematicida
UY34643A (es) Derivados de 5-alquinilo piridina como inhibidores de apoptosis,composiciones farmacéuticas y sus usos como miméticos smac
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
NI201400042A (es) 2 - tiopirimidinonas
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio